This article is more than 5 years old. Information may no longer be current.
ACIP's 2015 adult immunization schedule includes update for PCV13
Click Here to Manage Email Alerts
The Advisory Committee on Immunization Practices has published the recommended 2015 adult immunization schedule in MMWR.
The schedule was reviewed and approved by the American College of Physicians, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, and American College of Nurse-Midwives.
The most significant change is the inclusion of routine administration of Prevnar 13, the 13-valent pneumococcal conjugate vaccine (PCV13, Pfizer) as part of a pneumococcal vaccine series for adults aged 65 years and older. The ACIP recommended the vaccine in August 2014 for this age group. Patients are recommended to receive Prevnar 13, followed by Pneumovax 23, the 23-valent pneumococcal polysaccharide vaccine (PPSV23, Merck).
Footnotes for the pneumococcal vaccine recommendation now include patient-based algorithms and guidance for health care providers to make appropriate vaccination decisions for patients, depending on their pneumococcal vaccine history.
Influenza vaccine recommendations footnote changes include the FDA approval to expand the approved age for use of the recombinant influenza vaccine. The vaccine now is indicated for adults aged 18 years and older, rather than adults aged 18 to 49 years.
Age 49 years remains the upper age limit for the live-attenuated influenza vaccine. The schedule also includes revisions on precautions and contraindications related to the LAIV.
Click Here to Manage Email Alerts